By the end of 2029, the market for treatments for canine atopic dermatitis is expected to surpass US$ 2.37 billion. The market is expected to grow as greater focus is given on the discovery of new therapies, such as monoclonal antibodies, for the treatment of atopic dermatitis in dogs and cats.
The market for treatments for canine atopic dermatitis is expanding at a phenomenal Compound Annual Growth Rate (CAGR). This increase highlights the growing need for practical treatments for canine atopic dermatitis. A significant paradigm change occurs in the market for therapies for atopic dermatitis as knowledge of canine health and well-being rises.
Global revenue s of canine atopic dermatitis treatment market will surpass US$ 2.4 Billion in 2029. The growth in market value will be staggering, accredited to advancements in biotechnology, gene therapy, digital innovations, and increased investments from market players, as indicated by a new FMI report.
“Sales of canine atopic dermatitis treatment drugs and vaccines will continue to surge at an impressive rate owing to innovations in novel drug development in veterinary science. In view of enhanced resistance towards certain therapeutic agents, the demand for immune-specific vaccines and drugs is witnessing an upswing,” says the FMI analyst.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-4412
Key Takeaways of Canine Atopic Dermatitis Treatment Market Study
- Immunosuppressant drugs that currently lead the market will lose their market share to monoclonal antibodies (mAb).
- Oral administration remains at the forefront of preferred drug intake method.
- Injectable drugs will witness a steady CAGR and will rise to prominence by 2029, surpassing oral administration.
- Retail pharmacies continue to hold the leading revenue share; veterinary clinics closing in.
- Gains in canine atopic dermatitis treatment market are concentrated in North America.
Top Growth Drivers
- Established players in human life sciences are investing significant pecuniary resources in veterinary science, ascertaining the market growth.
- Robust healthcare infrastructure and rising pet ownership are bolstering the growth of market in North America.
- Swift recovery and less side effects remain the growth levers fueling demand for injectable veterinary drugs.
- Increasing online availability and easy accessibility of medical information will continue to be the significant growth contributor.
Key Restraints
- Certain therapeutic agents are facing increasing resistance, which is limiting the demand for immunosuppressant drugs.
- Ineffectual management by healthcare providers is a major hindrance to market growth.
Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-4412
Competitive Landscape
Leading players in global canine atopic dermatitis treatment market include, but are not limited to, Elanco Animal Health, Zoetis, Boragen Inc., and Immunomic Therapeutics Inc. Industry giants are focused on strategic alliances with regional players to boost their global presence. They continue to direct substantial resources towards regional acquisitions in order to fortify their market foothold. For instance, Zoetis acquired Nexvet Biopharma (2018) to accelerate the development of mAb therapies. This would enable the company to create new alternatives for treating canine atopic dermatitis. On the other hand, Elanco Animal Health acquired Boehringer Ingelheim Vetmedica, Inc. (2017), to innovate their range of rabies vaccines, canine and feline products.
Key Segments:
By Drug Class :
- Corticosteroids
- Immunosuppressants
- Antibiotics
- Antihistamines
- Emollients
- Essential Fatty Acids
- Antipruritics
- Monoclonal Antibodies
By Route of Administration :
- Topical
- Oral
- Injectable
By Distribution Channel :
- Veterinary Hospitals
- Veterinary Clinics
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube